[go: up one dir, main page]

WO2023187639A1 - Molécules d'acide nucléique fonctionnelles pour la régulation épigénétique - Google Patents

Molécules d'acide nucléique fonctionnelles pour la régulation épigénétique Download PDF

Info

Publication number
WO2023187639A1
WO2023187639A1 PCT/IB2023/053072 IB2023053072W WO2023187639A1 WO 2023187639 A1 WO2023187639 A1 WO 2023187639A1 IB 2023053072 W IB2023053072 W IB 2023053072W WO 2023187639 A1 WO2023187639 A1 WO 2023187639A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
regulating system
sequence
nucleic acid
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2023/053072
Other languages
English (en)
Inventor
Angelo SERANI
Valter Tucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Istituto Italiano di Tecnologia
Original Assignee
Fondazione Istituto Italiano di Tecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Istituto Italiano di Tecnologia filed Critical Fondazione Istituto Italiano di Tecnologia
Priority to EP23717258.0A priority Critical patent/EP4499152A1/fr
Publication of WO2023187639A1 publication Critical patent/WO2023187639A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Definitions

  • the present invention relates to a gene regulating system comprising : 1 ) a functional nucleic acid molecule comprising : a first portion comprising at least one sequence coding for a dCAS 12 f protein lacking nuclease activity and maintaining the ability to anchor to a target DNA sequence , and at least one second portion comprising a sequence coding for an epigenetic enzyme or enzymatically active portion thereof ; and at least one promoter upstream of the first portion; and 2 ) a guide RNA or DNA encoding therefor, which is capable of recogni zing the target DNA sequence and directing said dCAS 12 f protein thereto , wherein the functional nucleic acid molecule and the DNA encoding for the guide RNA are included in the same nucleic acid molecule .
  • Methylation at 5-cytosine is a natural DNA biochemical modification.
  • the 5mC methylation is a dynamic and reversible process mainly mediated in humans by DNA methyltransferase (DNMT-1, DNMT-3A, and DNMT-3B) .
  • the demethylation is primed by Ten-eleven translocation (TET) that oxidates the 5mC to 5- hydroxymethylated C (5-hmC) .
  • TET Ten-eleven translocation
  • the 5-hmC represents the starting signal for a further cascade of reactions that lead to the unmethylated cytosine.
  • DNA Methylation regulates the accessibility of chromatin, the binding of specific transcription factors to the gene promoter, and the assembling of the transcription machinery.
  • CRISPRs clustered regularly interspaced palindromic repeats
  • Cas CRISPR-associated proteins
  • CRISPR technology is based on DNA breaks and homology-directed repair mechanisms, which can be programmed by noncoding single guide RNAs (sgRNAs) to guide specific nuclease (Cas9) to induce site-specific DNA cleavage in virtually any cellular system and organism.
  • sgRNAs noncoding single guide RNAs
  • Cas9 guide specific nuclease
  • Single-strand nicks bring significant potential cellular toxicity, making these approaches less suitable for therapeutic strategies.
  • CRISPR application in human disease treatments presents a number of limitations that still prevent its application in most human gene therapy .
  • This invention is instrumental in preventing and correcting human disorders as well as developing ad hoc treatments for common symptoms across diseases , overall developing new classes of precise gene-based treatments ( e . g . , precise epi-gene therapy) .
  • This obj ect is achieved by means of the gene regulating system as defined in claim 1 .
  • obj ects of the present invention are to provide medical uses of the gene regulating system as defined in claims 5 to 9 .
  • nucleic acid molecule By “functional nucleic acid molecule” there is generally intended that the nucleic acid molecule is capable of inducing methylation or demethylation of a target DNA of interest . In particular, this activates or inactivates gene expression by modi fying the epigenetic elements that regulate the transcriptional machinery of the target gene .
  • the "CRISPR” is a microbial immune system involved in defense against invading exogenous DNA material .
  • the CRISPR loci in microbial hosts contain a combination of CRISPR- associated (Cas) genes as well as noncoding RNA elements capable of programming the specificity of the CRISPR- mediated nucleic acid cleavage.
  • Cas9 forms a complex with the 3' end of the single guide RNA (“sgRNA”) , and the protein-RNA pair recognizes its genomic target by complementary base pairing between the 5' end of the sgRNA sequence and a predefined 20 bp DNA sequence, known as the protospacer.
  • sgRNA single guide RNA
  • the Cas9 nuclease can be directed to new genomic targets.
  • CRISPR spacers are used to recognize and silence exogenous genetic elements in a manner analogous to RNAi in eukaryotic organisms.
  • An engineered form of the effector system of Streptococcuspyogenes was shown to function in human cells for genome engineering.
  • the Cas9 protein can be directed to genomic target sites by a synthetically reconstituted "guide RNA" ("gRNA") .
  • gRNA guide RNA
  • Target recognition occurs upon detection of complementarity between a "protospacer" sequence in the target DNA and the remaining spacer sequence in the gRNA.
  • Cas9 mediates cleavage of target DNA if a correct protospacer adjacent motif (PAM) is also present at the 3' end of the protospacer.
  • PAM protospacer adjacent motif
  • the S. pyogenes CRISPR system may have the PAM sequence for this Cas9 (SpCas9) as 5 ' -NRG- 3' , where R is either A or G, and characterized the specificity of this system in human cells.
  • SpCas9 SpCas9
  • a unique capability of the CRISPR/Cas9 system is the straightforward ability to simultaneously target multiple distinct genomic loci by co-expressing a single Cas9 protein with two or more s gRNAs .
  • CRISPR-Casl2f is a family of exceptionally compact RNA-guided nucleases from uncultivated archaea. Originally identified as a single-stranded DNA (ssDNA) cutter, the wildtype Casl2f (also known as Casl4) system was recently discovered to possess PAM sequences for double-stranded DNA cleavage in vitro. The Casl2f system has no detectable activity in mammalian cells but RNA engineering and protein engineering can be applied to this isoform to generate a compact, efficient, and specific system for mammalian genome engineering (which is also referred to as CasMINI) .
  • CasMINI mammalian genome engineering
  • This provides a new method to engineer compact and efficient CRISPR-Cas effectors that can be useful for broad genome engineering applications, including gene regulation, gene editing, base editing, epigenome editing, and chromatin imaging.
  • the Casl2f can be mutated to generate amino acid substitutions D326A and D510A and obtain the nuclease- inactivated dCasl2f.
  • Casl2f and its derivate dCasl2f possess a TTTR PAM.
  • dCasl2f can be ligated to epigenetic writers to modify the epigenetic regulation of specific target.
  • MSssI refers to the DNA methylase of Spiroplasma sp .
  • strain MQ1 which displays the same sequence specificity as that of the known mammalian DNA methylases.
  • the sequence specificity of this methylase is characterized by methylating exclusively CpG sequences, making it a convenient tool for studying DNA methylation in eukaryotes.
  • MSssI a CpG methylase is the first discovered prokaryotic DNA methylase able, firstly to recognize CpG dinucleotide sequence and it shares this recognition sequence with the eukaryotic DNA methylase.
  • Spiroplasma is a plant parasite and it is possible that this bacteria inherited the gene from its eukaryotic host.
  • TET1 Teten-eleven translocation methylcytosine dioxygenase 1
  • TET1 Ten-eleven translocation methylcytosine dioxygenase 1
  • the full structure of TET1 includes a double-stranded p-helix (DSBH) domain, a cysteine-rich domain, and a CXXC domain.
  • the dioxygenase activity of DSBH is dependent on Fe2+ and 2-oxoglutarate (2- OG) .
  • Double-stranded /? -helix is the active catalytic subunit, which oxidizes the methyl group attached to the 5' position of C.
  • the function of the cysteine-rich domain is to stabilize the TET-DNA interaction.
  • TET1 catalyses the hydroxylation of DNA methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) , and it can further oxidize 5hmC into 5-formylcytosine (5fC) and 5-carboxycytosine (5caC) .
  • 5fC and 5caC are mostly unstable, as they can be rapidly excised by thymine DNA glycosylase (TDG) in an active de-methylation state.
  • TDG thymine DNA glycosylase
  • TET1 directly interacts with transcription factors and histone modification enzymes to regulate gene expression.
  • Figure 1 shows a schematic representation of the generation of a vector (miniOFF-1) according to one embodiment of the present invention
  • Figure 2 shows a schematic representation of the generation of a vector ( aavOFF- 1 ) according to another embodiment of the present invention
  • Figure 3 shows a schematic representation of the generation of a vector (miniON) according to another embodiment of the present invention
  • Figure 4 shows a schematic representation of the generation of a vector ( aavON- 1 ) according to another embodiment of the present invention
  • Figure 5 shows a schematic representation of the strategy to generate AAV containing the gene regulating system according to an embodiment of the present invention
  • Figure 6 shows a schematic representation of the promoter sequence regulating the expression of the human gene MGMT and the consensus sequence for the guide included in the vector named TUSER+sgMGMT of Example 6 .
  • Figure 7 shows a schematic representation of the promoter sequence regulating the expression of the human gene PARP1 and the consensus sequence for the guide included in the vector named TUSER+sgPARPl of Example 6 .
  • Figures 8 to 11 show graphs of the methylation of the PARP1 and MGMT promoters and of the expression of the PARP1 and MGMT mRNAs .
  • Figure 12 shows a graph of cell viability after TUSER and temozolomide treatment .
  • Figure 13 shows a schematic representation of the promoter sequence regulating the expression of the human gene HCRT and the consensus sequence for the guide included in the vector named TUSER+sgHCRT of Example 7 .
  • Figure 14 shows the endogenous expression of the cell lines used in the example 7 .
  • Figure 15 shows the methylation of the HCRT promoter in the Hek293T cell treated with TUSER+sgHCRT compared to the cell treated with the control vector of the example 7 .
  • Figure 16 shows the mRNA expression of the human HCRT gene in the Hek293T cell treated with TUSER+sgHCRT compared to the cell treated with the control vector of the example 7 .
  • Figure 17 shows the expression level of the TET1CD mRNA encoded in the construct aavON- 1 compared to the endogenous level of the TET in the HEK293T cells .
  • Figure 18 show the expression level of the dCas l2 f encoded in the aavON- 1 construct compared the public available miniCAS construct .
  • a gene regulating system according to the present invention comprises :
  • first portion comprising at least one sequence coding for a dCAS 12 f protein lacking nuclease activity and maintaining the ability to anchor to a target DNA sequence
  • second portion comprising a sequence coding for an epigenetic enzyme or enzymatically active portion thereof
  • RNA or DNA encoding therefor which is capable of recognizing the target DNA sequence and directing said dCAS12f protein thereto, wherein the functional nucleic acid molecule and the DNA encoding for the guide RNA are included in the same nucleic acid molecule
  • dCAS12f has sequence SEQ ID NO: 7.
  • the CAS protein is engineered to a minimal DNA sequence that can still produce a protein lacking nucleases activity and be used as DNA anchoring to target specific DNA sequences, with the epigenetic enzyme, which is preferably Spiroplasma methyltransferase MQ1 (more preferably SEQ ID NO: 8) or the catalytic domain of the human Tet Methylcytosine Dioxygenase 1 (TET1CD) (more preferably SEQ ID NO: 9) .
  • the reduced (minimal) size of constructs makes this programmable epigenome editing technology suitable for delivery with an adeno-associated virus (AAV) .
  • the gene regulating system may contain regulatory elements suitable for the specific tissue or cell expression in the host organisms .
  • the first portion is a fusion protein between dCasl2f, and two different epigenetic writers such as the sssIM de novo methyltransferase from MQ1 Spiroplasma or the catalytic domain of the human Tet Methylcytosine Dioxygenase 1 (TET1CD) .
  • the MQ1 methyltransferase catalyzes the addition of a methyl group (CH3) to the cytosine of the cytosine-guanidine dinucleotide (CpG) in the DNA sequence.
  • the TET1CD protein catalyzes the modification of the methyl-cytosine in the DNA to a hydroxyl-methyl-cytosine leading to the removal of the methyl group from the cytosine residue.
  • the methylation of a gene promoter induces robust gene silencing, whereas the de-methylation of such sequence activates the gene expression.
  • the recruitment of MQ1 or TET1CD on the gene promoter may positively and negatively modulate the gene expression, respectively.
  • the at least one promoter upstream of the first portion is preferably a CMV or PGK promoter. More preferably the CMV promoter has sequence SEQ ID NO:1 and the PGK promoter has sequence SEQ ID NO: 2.
  • the product of the above said functional nucleic acid molecule is directed to the specific DNA target by administering specific guide RNA.
  • the guide RNA is a specific RNA sequence that recognizes the target DNA region of interest and directs the Gas nuclease there for editing.
  • the gRNA is made up of two parts: crispr RNA (crRNA) , a 17-20 nucleotide sequence complementary to the target DNA, and a tracr RNA, which serves as a binding scaffold for the Gas nuclease.
  • the Gas nuclease binds to its target sequence only in the presence of a specific sequence, called protospacer adjacent motif (PAM) , on the non-targeted DNA strand flanking the consensus sequence of the guide.
  • PAM protospacer adjacent motif
  • the 17-20 nucleotides targeted sequence must be flanked by three nucleotides 5 Z -NGG-3 (where N consists in any nucleotide) .
  • Overall the guide must be composed of the targeting sequence (herein referred as guide) , the PAM motif, and the relative scaffold sequence to anchor the guide to the respective Gas.
  • the overall length of the guide ranges from 60 to 80 bases and the relative cDNA sequence can be cloned in an RNA- expressing vector under the control of RNA polymerase I I I promoters such as U6 .
  • the gene regulating system therefore comprises the above disclosed functional nucleic acid and a guide RNA or DNA encoding therefor, which is capable of recogni zing the target DNA sequence and directing said CAS protein thereto .
  • TUSER targeting unit for speci fic epigenetic remodeling
  • TUSER targeting unit for speci fic epigenetic remodeling
  • TUSER can be used to target a large set of genes within the mammalian genome .
  • Modules of this system exploit Cas ability to bind a DNA sequence after the administration of a target-speci fic RNA guide .
  • Opposite epigenetic writers substitute dCas 9 cleaving activity characteri zing the core elements of this system : Meth-OFF and Meth-ON cassettes .
  • the reduced dimension of the TUSER constructs gives the possibility to include speci fic guideexpressing cassettes in the same AAV .
  • the DNA encoding for a guide RNA, which is capable of recogni zing the target DNA sequence and directing said CAS protein thereto , and the functional nucleic acid molecule are preferably included in the same nucleic acid molecule , preferably an adeno-associated virus (AAV) vector .
  • AAV adeno-associated virus
  • the DNA encoding for the guide RNA expressed by a speci fic U6 promoter that recruits the RNA polymerase class I I I , is cloned downstream the epigenetic writer cassette in the opposite direction with respect to the coding sequence .
  • This strategy induces epigenetic remodeling mediated by the administration of a single AAV containing both the epigenetic writer and the guide for a particular genetic region to treat a range of diseases .
  • the constructs according to the present invention are preferably designed to be suitable for adeno-associated virus packaging .
  • adeno-as sociated viral (AAV) vectors have emerged as a favored gene trans fer system for this approach .
  • AAV adeno-as sociated viral
  • AAV is particularly ef ficient in the transduction of non-dividing cells , and the vector genome persists predominantly in episomal forms .
  • Substantial correction, and in some instances complete cure , of genetic disease has been obtained in animal models of hemophilia, lysosomal storage disorders , retinal diseases , disorders of the central nervous system, and other diseases , including brain tumors .
  • glioblastoma is one of the most malignant primary brain tumours with an aggressive phenotype and a poor very short survival rate outcome caused by the inef fectiveness of current treatments .
  • Temozolomide ( TMZ ) represents the current standard of treatment .
  • TMZ By al kylating guanine residues , TMZ induces futile DNA mismatch repair that introduces single-stranded breaks resulting in replication fork arrest and cell death .
  • Two main DNA repairing programs in the cells cause the dominant mechanism of TMZ resistance .
  • the DNA repair enzyme 06-methylguanine- DNA methyltrans ferase (MGMT ) removes alkylated guanine bases to counter the lethal ef fects of the drug .
  • poly (ADP-ribose ) polymerase 1 ( PARP1 ) expression enhances the base scissor repair system repairing DNA breaks provided by TZM ( Fig) .
  • TZM poly (ADP-ribose ) polymerase 1
  • MGMT or PARP1 expression is suppressed by methylation tend to be highly responsive to TMZ , with an increase in median survival of approximately six and one-hal f months compared to less than one month for cancer expressing these proteins .
  • MGMT promoter hypermethylation occurs in less than 50% of primary GBM patients , whereas PARP1 is normally expressed in the cells .
  • the gene regulating system according to the present invention has been trans fected into primary GBM prior to TMZ treatment cells to increase MGMT or PARP1 promoter methylation and hij ack GBM resistance .
  • the gene regulating system according to the present invention can therefore be used as a medicament .
  • the gene regulating system can induce upregulation or downregulation of the expression of a gene in a human individual in which said gene is respectively pathologically underexpressed or overexpressed .
  • the gene regulating system according to the present invention is used in treating cancer .
  • the cancer is preferably glioblastoma .
  • the gene regulating system according to the present invention can also be applied to reinforce speci fic treatments .
  • it can be used as a strategy to prevent chemotherapy resistance , such as glioblastoma multi forme ( GBM) treatment with temozolomide .
  • the gene regulating system according to the present invention can also be applied to gene haploinsuf f iciency or overexpression cases .
  • the technology according to the present invention was validated by designing experimental applications that have the potential to impact various physiological domains such as cancer biology .
  • Casl2f small CRISPR-associated effector proteins belong to the type V-F subtype of the Cas family.
  • the sequence encoding for a nuclease-deactivated Casl2f (dCasl2f) is commercially available as a bacterial plasmid (Addgene inc., plasmid #176269) where a PGK promoter expresses the coding sequence.
  • a PGK promoter expresses the coding sequence.
  • the binding site for the endonuclease Nhel present in the vector was inactivated by site direct mutagenesis, downstream the coding sequence, and introduced the binding site for this endonuclease at 3' position of the miniCAS coding sequence.
  • the vector (Addgene inc, plasmid #89793) was mutated to introduce the binding sequence for the endonucleases Spel at the 5' end of the MQ1 sequence, and the binding sequence for the endonuclease EagI the 3' end of the sequence.
  • the PGK-dCasl2f was treated with Nhel and EagI, whereas the mutated MQ1 plasmids were treated with Spel and EagI .
  • the final vector was obtained by ligating the Nhel-PGK- dCasl2f-EagI fragment with the Spel-MQl-Eagl fragment to obtain the final construct miniOFF-1.
  • the sequence of miniOFF-1 was amplified by PGR using a set of two primers, presenting the binding sequence for Nhel and BamHI, respectively.
  • the amplified was used to include the miniOFF-1 in the pAAV-MCS2 vector (Addgene Plasmid #46954) .
  • Both the pAAV-MCS2 vector and the amplified were treated with Nhel and BamHI endonucleases and the NheI-pAAV-MCS2-BamHI fragment was ligated to the Nhel-miniOFF-l-BamHI fragment to obtain the aavOFF-1.
  • a synthetic cassette containing the U6 promoter followed by the guide sequence and a small terminator sequence was cloned downstream the transcriptional terminator WPRE in the opposite direction respecting the dCasl2f-MQl coding sequence.
  • the binding site for the endonuclease Nhel downstream the coding sequence was inactivated by mutation and the binding site for this endonuclease introduced at 3' position of the miniCAS coding sequence.
  • the catalytic domain of the TET1 gene was cloned by PCR by two pairs of primer containing the Spel and the EagI binding sites .
  • the PGK-dCasl2f was treated with Nhel and EagI, whereas the amplified TET1CD sequence was treated with Spel and EagI.
  • the final vector was obtained by ligating the Nhel-PGK- dCasl2f-EagI fragment with the SpeI-TS-ON-3-EagI fragment to obtain the final construct miniON-1 (Fig. 9G) .
  • the sequence of miniON-1 was amplified by PCR using a set of two primers, presenting the binding sequence for Nhel and for BamHI, respectively.
  • the amplified was used to include the miniON-1 in the pAAV- MCS2 vector.
  • Both the pAAV-MCS2 vector and the amplified were treated with Nhel and BamHI endonucleases, and the Nhel- pAAV-MCS2-BamHI fragment was ligated to the NheI-miniON-1- BamHI fragment to finally obtain the aavON-1.
  • Example 5 applications for AAV-OFF and AAV-ON
  • AAVs are one of the most actively investigated gene therapy vehicles . They are non-enveloped viruses that can be engineered to deliver DNA to target cells and have attracted signi ficant attention in the field, especially in clinical-stage experimental therapeutic strategies .
  • the ability to generate recombinant AAV particles lacking any viral genes and containing DNA sequences of interest for various therapeutic applications has thus far proven to be one of the safest strategies for gene therapies .
  • the small ( 4 . 8 kb ) ssDNA AAV genome consists of two open reading frames , Rep and Cap, flanked by two 145 base inverted terminal repeats ( ITRs ) . These ITRs base pair to allow for the synthesis of the complementary DNA strand .
  • Rep and Cap are translated to produce multiple distinct proteins (Rep78 , Rep68 , Rep52 , Rep40 , required for the AAV li fe cycle and VP1 , VP2 , VP3 for the capsid proteins ) .
  • the transgene is placed between the two ITRs , and Rep and Cap are supplied in trans .
  • AAV requires a helper plasmid containing genes from adenovirus . These genes (E4 , E2a, and VA) mediate AAV replication .
  • the trans fer plasmid, Rep/Cap, and the helper plasmid are trans fected into producing cells (e.g., HEK293 cell line) , which contain the adenovirus gene E1+, to produce infectious AAV particles.
  • Rep/Cap and the adenovirus helper genes may also be combined into a single plasmid; the separation of Rep and Cap shown in the figure on the right facilitates the viral pseudotyping discussed below.
  • the mini-OFF or the mini-ON coding TUSER sequence and the guide of the Casl2f to the specific target gene can be cloned between the two ITRs and packaged into the final AAV particles.
  • the AAV-OFF and AAV-ON vectors were produced by cloning the mini-OFF and mini-ON cassette into a pAAV-MCS2 vector.
  • This vector encodes the genes necessary to produce a serotype 2 AAV (AW2) .
  • AW2 AAV serotype 2 AAV
  • This serotype is suitable for transducing the genetic content specifically into the central nervous system, kidney, or retinal photoreceptor cells.
  • the AAV production technique can be instrumental in producing any commercial AAV serotype by replacing the pAAV-MCS2 with the respective serotype vector.
  • the coding sequence of aavOFF and aavON vectors contain the dCasl2f fused to the respective MQ1 or TET1CD coding sequence.
  • a WPRE sequence terminates the epigenetic writer's transcription and stabilizes the produced mRNA.
  • cassettes expressing the gRNA for a specific target was included.
  • Such cassettes can be composed of a U6 promoter, the coding sequence of the guide and a small transcriptional terminator sequence.
  • the U6 promoter recruits the RNA polymerase III to transcribe the gRNA sequence .
  • Such a designed construct can be used to create an AAV expressing both the epigenetic writer and the target-speci fic guide in the same delivery vector .
  • Gliomas are the most common primary brain tumours in adults . Despite the progress made in the molecular aspects of malignant gliomas , the prognosis of brain tumours continues to be dismal . Glioblastoma multi form ( GBM) is a highly aggressive brain tumour with a median patient survival of 14 . 6 months . Chemotherapy has been used for decades to treat GBM, and the oral methylator temozolomide ( TMZ ) is currently the most widely used chemotherapeutic agent . TMZ achieves cytotoxicity mostly by methylating the 06 position of guanine ( 0me 6G) .
  • the 06-methylguanine DNA methyltrans ferase can reverse alkylation at the 06 position of guanine and neutrali ze the cytotoxic ef fects of alkylating agents .
  • MGMT expression in brain tumors represents a key mechanism of resistance toward alkylating agent therapy .
  • TMZ induces not only 0me 6G but also large numbers of N3-methyladenine and N7 -methylguanine adducts that are rapidly processed by the base excision repair (BER) DNA repair pathway .
  • BER base excision repair
  • N3-methyladenine and N7- methylguanine lesions activate the nuclear enzyme poly-ADP- ribose-polymerase 1 ( PARP1 ) , which synthesi ze poly-ADP- ribose chains and facilitate the recruitment of XRCC1 , pol- beta, and DNA ligase to repair the DNA strand break sites .
  • PARP1 poly-ADP- ribose-polymerase 1
  • MGMT sgRNA consists of a guide targeting the consensus sequence at 248 bases upstream of the MGMT TSS (FIGURE 6, sgRNA-1 - dark arrow)
  • PARP1 is designed to target the consensus sequence located 338 bp upstream the TSS of the PARP1 gene (FIGURE 7, sgRNA-1 - dark arrow) .
  • Each guide was included in the vector coding for the epigenetic writer named aavOFF-1 ( Figure 2) , here referred as TUSER+sgMGMT and TUSER+sgPARPl , and used to treat the glioblastoma cell lines.
  • the control vectors were produced by delating the relative sgRNA guide of the plasmids.
  • U118 cell line procured from the American Tissue Collection Center (ATCC, Manassas VA) , was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin and maintained at 37°C and 5% C02. Transfections were performed in 12-well plates using 1000 ng of the respective TUSER+sgMGMT and TUSER+sgPARPl expression vector mixed with Lipof ectamine 2000 (Life Technologies, cat. # 11668019) as per manufacturer's instruction.
  • DMEM Dulbecco's modified Eagle's medium
  • the methylation assay uses a pair of restriction enzymes, MspI and Hpall with different sensitivity to methylation to analyze DNA methylation status at a specific sequence.
  • MspI and Hpall are isoschizomers with CCGG specificity. When the internal CpG in 5'-CCGG-3' tetranucleotide is methylated, cleavage with Hpall is blocked, but cleavage with MspI is not affected.
  • genomic DNA samples were extracted from the trated cells using Trizol reagent (thermofisher) . 1 ug of the samples' genomic DNA was incubated for 1 hour at 37 °C with the two restriction enzymes separately. 25 ng of treated samples were used as templates in a qPCR analysis.
  • Cql is the threshold cycle of the "Undigested DNA” sample
  • nCq2 is the threshold cycle of the "Digested with Hpall” sample
  • Cq3 is the threshold cycle of "Digested with Epi MspI” sample
  • E is the PGR efficiency value (%) mRNA expression by qPCR
  • Gliomas are the most common primary brain tumors in adults. Despite the progress made in the molecular aspects of malignant gliomas, the prognosis of brain tumors continues to be dismal. Glioblastoma multiform (GBM) is a highly aggressive brain tumor with a median patient survival of 14.6 months. Chemotherapy has been used for decades to treat GBM, and the oral administration of temozolomide (TMZ) is currently the most widely used chemotherapeutic agent. TMZ achieves cytotoxicity mostly by methylating the 06 position of guanine (0me6G) .
  • the 06-methylguanine DNA methyltransferase can reverse alkylation at the 06 position of guanine and neutralize the cytotoxic effects of alkylating agents.
  • MGMT expression in brain tumors represents a key mechanism of resistance toward alkylating agent therapy (GIT MGMT Zhi-Kun Qui) .
  • TMZ induces not only 0me6G but also large numbers of N3-methyladenine and N7-methylguanine adducts that are rapidly processed by the base excision repair (BER) DNA repair pathway.
  • N3- methyladenine and N7-methylguanine lesions activate the nuclear enzyme poly-ADP-ribose-polymerase 1 (PARP1) , which synthesize poly-ADP-ribose chains and facilitate the recruitment of XRCC1, pol-beta, and DNA ligase to repair the DNA strand break sites.
  • PARP1 poly-ADP-ribose-polymerase 1
  • DMSO Dimethylsulphoxide
  • Transfected cells were treated with 0.5 uM of TZM, 48 after the transfection, and incubated for 48 hours before further analysis.
  • Cell viability assay was performed with automated cell counter LunaTI (Twinx Helix inc.) .Treated cells were collected from the experimental plates and placed on the counting chip according to the manufacturer protocols. Cell counting were represented number of cell counted in each condition and compared to the sample treaded with TUSER-Mock + TMZ without the guide.
  • the U118 cells were transfected with the vectors TUSER+sgMGMT, TUSER+sgPARPl and the Mock vector encoding for the TUSER aavOFF-1 where the respective guide sequences were deleted. Both the MGMT and the PARP-1 targeting constructs were able to upregulate the methylation of the respective promoter sequence ( Figures 8 and 10) , in a region between the amplification primers sequence ( Figures 6 and 7) . The methylation of the promoter sequences led to a downregulation of the mRNA expression of PARP1 ( Figure 9) and MGMT ( Figure 11) .
  • Example 7 Demethylation of HCRT gene by aavON-1
  • HCRT sgRNA consists of a guide targeting the consensus sequence at 256 bases upstream of the HCRT TSS (FIGURE 13, sgRNA-1 - dark arrow) .
  • the guide was included in the vector coding for the epigenetic writer named aavON-1 ( Figure 4) , here referred as TUSER+sgHCRT, and used to treat the HEK293T cell line.
  • the control vectors were produced by delating the relative sgRNA guide of the plasmids .
  • HEK293T, Hela, T98G, U118 and U87 cell lines procured from the American Tissue Collection Center (ATCC, Manassas VA) , was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin and maintained at 37°C and 5% C02.
  • DMEM Dulbecco's modified Eagle's medium
  • the expression level of HCRT gene was measured by RT-PCR and the HEK293T cells was userd for further analysis of the TUSER+sgHCRT effect. Transfections were performed in 12-well plates using 1000 ng of the TUSER+sgHCRT expression vector mixed with Lipof ectamine 2000 (Life Technologies, cat. # 11668019) as per manufacturer's instruction.
  • the methylation assay uses a pair of restriction enzymes, MspI and Hpall with different sensitivity to methylation to analyze DNA methylation status at a specific sequence.
  • MspI and Hpall are isoschizomers with CCGG specificity. When the internal CpG in 5'-CCGG-3' tetranucleotide is methylated, cleavage with Hpall is blocked, but cleavage with MspI is not affected.
  • genomic DNA samples were extracted from the trated cells using Trizol reagent (thermofisher) . 1 ug of the samples' genomic DNA was incubated for 1 hour at 37 °C with the two restriction enzymes separately. 25 ng of treated samples were used as templates in a qPCR analysis.
  • Cql is the threshold cycle of the "Undigested DNA” sample
  • nCq2 is the threshold cycle of the "Digested with Hpall” sample
  • Cq3 is the threshold cycle of "Digested with Epi MspI” sample
  • E is the PGR efficiency value (%) mRNA expression by qPCR
  • the HEK293T cells were transfected with the vectors TUSER+sgHCRT and the Mock vector encoding for the TUSER aavON-1 where the respective guide sequences were deleted, the HCRT targeting constructs were able to upregulate the methylation of the promoter sequence ( Figures 15) , in a region between the amplification primers sequence ( Figures 13) .
  • the present invention provides a gene regulation system that allows precise and reversible epigenetic manipulation to both in vivo and in vitro laboratory applications and provides access to gene expression manipulation for laboratories that are not prepared for complex biosafety levels of virus handling . Because of the reduced dimension of TUSER, it can be delivered by a simple adeno-associated virus (AAV) and then requiring a low biosafety level ( e . g . , BS 1 ) •
  • AAV simple adeno-associated virus
  • the TUSER system is customi zable , which means that by designing speci fic RNA guides that are suited to the modi fied CAS protein, it represents a novel tool to transiently modi fy DNA methylation at speci fic sites and in various experimental systems ( e . g . , inducible stem cells , primary neurons... ) .
  • This system overcomes the di f ficulties of providing ef ficient protocols to apply CRISPR methods and, the re-combinable stop cassettes make TUSER highly speci fic in tissue expression .
  • the presence of both methyltrans ferases and demethylases provides a flexible tool that positively or negatively regulates gene expression and its epigenetics by merely changing the chemical compound used to treat the mouse .
  • the biological material at the basis of the invention derives from cloned synthetic molecules obtained by using information retrieved from online sequence databases .
  • Biological material of animal origin used in the invention comes from United Kingdom (UK) and relates to Mus musculus .
  • Biological material of human origin used in the invention has been acquired pursuant to the applicable provisions of law .
  • cell lines have been regularly purchased from the sources stated in the above description .
  • any biological material containing microorganisms or genetically modi fied organisms used in the invention has been treated meeting the provisions of law relating to such modi fications .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un système de régulation génétique est divulgué, comprenant : une molécule d'acide nucléique fonctionnelle comprenant : une première partie comprenant au moins une séquence codant pour une protéine dCAS12f dépourvue d'activité nucléase et maintenant la capacité d'ancrage à une séquence d'ADN cible et au moins une seconde partie comprenant une séquence codant pour une enzyme épigénétique ou une partie enzymatiquement active de celle-ci ; au moins un promoteur en amont de la première partie ; ainsi qu'un ARN guide ou un ADN codant pour celui-ci, qui est apte à reconnaître la séquence d'ADN cible et à diriger ladite protéine dCAS12f sur celle-ci, la molécule d'acide nucléique fonctionnelle et l'ADN codant pour l'ARN guide étant inclus dans la même molécule d'acide nucléique.
PCT/IB2023/053072 2022-03-30 2023-03-28 Molécules d'acide nucléique fonctionnelles pour la régulation épigénétique Ceased WO2023187639A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23717258.0A EP4499152A1 (fr) 2022-03-30 2023-03-28 Molécules d'acide nucléique fonctionnelles pour la régulation épigénétique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102022000006296 2022-03-30
IT102022000006296A IT202200006296A1 (it) 2022-03-30 2022-03-30 Molecole di acido nucleico funzionali per regolazione epigenetica

Publications (1)

Publication Number Publication Date
WO2023187639A1 true WO2023187639A1 (fr) 2023-10-05

Family

ID=82100393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/053072 Ceased WO2023187639A1 (fr) 2022-03-30 2023-03-28 Molécules d'acide nucléique fonctionnelles pour la régulation épigénétique

Country Status (3)

Country Link
EP (1) EP4499152A1 (fr)
IT (1) IT202200006296A1 (fr)
WO (1) WO2023187639A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025243196A1 (fr) * 2024-05-21 2025-11-27 Fondazione Istituto Italiano Di Tecnologia Système de régulation génique (tuser)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018154096A1 (fr) * 2017-02-24 2018-08-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Méthode de réexpression de différents gènes hyperméthylés impliqués dans la fibrose, comme rasal1 hyperméthylé et son utilisation dans le traitement de la fibrose ainsi que kit de pièces pour réexpression de gènes hyperméthylés comprenant rasal1 chez un sujet
WO2021081135A2 (fr) * 2019-10-21 2021-04-29 The Regents Of The University Of California Compositions et méthodes d'édition du gène cdkl5

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018154096A1 (fr) * 2017-02-24 2018-08-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Méthode de réexpression de différents gènes hyperméthylés impliqués dans la fibrose, comme rasal1 hyperméthylé et son utilisation dans le traitement de la fibrose ainsi que kit de pièces pour réexpression de gènes hyperméthylés comprenant rasal1 chez un sujet
WO2021081135A2 (fr) * 2019-10-21 2021-04-29 The Regents Of The University Of California Compositions et méthodes d'édition du gène cdkl5

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KIM DO YON ET AL: "Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 40, no. 1, 2 September 2021 (2021-09-02), pages 94 - 102, XP037667066, ISSN: 1087-0156, [retrieved on 20210902], DOI: 10.1038/S41587-021-01009-Z *
KLEINSTIVER BENJAMIN P ET AL: "Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 37, no. 3, 11 February 2019 (2019-02-11), pages 276 - 282, XP037171464, ISSN: 1087-0156, [retrieved on 20190211], DOI: 10.1038/S41587-018-0011-0 *
PETER STEPPER ET AL: "CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter", NUCLEIC ACIDS RESEARCH, vol. 45, no. 4, 28 November 2016 (2016-11-28), GB, pages 1703 - 1713, XP055459985, ISSN: 0305-1048, DOI: 10.1093/nar/gkw1112 *
SAMRAT ROY CHOUDHURY ET AL: "CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter", ONCOTARGET, vol. 7, no. 29, 19 July 2016 (2016-07-19), United States, pages 46545 - 46556, XP055403302, ISSN: 1949-2553, DOI: 10.18632/oncotarget.10234 *
XU XIAOSHU ET AL: "Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing", MOLECULAR CELL, ELSEVIER, AMSTERDAM, NL, vol. 81, no. 20, 3 September 2021 (2021-09-03), pages 4333, XP086833228, ISSN: 1097-2765, [retrieved on 20210903], DOI: 10.1016/J.MOLCEL.2021.08.008 *
XU, X.CHEMPARATHY, A.ZENG, L.KEMPTON, H. R.SHANG, S.NAKAMURA, M.QI, L. S.: "Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing", MOLECULAR CELL, vol. 81, no. 20, 2021, pages 4333 - 4345, XP086833228, DOI: 10.1016/j.molcel.2021.08.008
YONG LEI ET AL: "Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein", NATURE COMMUNICATIONS, vol. 8, 11 July 2017 (2017-07-11), pages 16026, XP055459752, DOI: 10.1038/ncomms16026 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025243196A1 (fr) * 2024-05-21 2025-11-27 Fondazione Istituto Italiano Di Tecnologia Système de régulation génique (tuser)

Also Published As

Publication number Publication date
IT202200006296A1 (it) 2023-09-30
EP4499152A1 (fr) 2025-02-05

Similar Documents

Publication Publication Date Title
Li et al. Programmable base editing of mutated TERT promoter inhibits brain tumour growth
US11851656B2 (en) Chemically modified single-stranded RNA-editing oligonucleotides
Iyer et al. Efficient homology-directed repair with circular single-stranded DNA donors
CN114207130A (zh) 用于从白蛋白基因座进行转基因表达的组合物和方法
US20250277202A1 (en) Knockout of a mutant allele of an elane gene
US20240060088A1 (en) Guide RNA Designs and Complexes for Type V Cas Systems
WO2021050512A1 (fr) Nouvelles enzymes crispr, procédés, systèmes et utilisations associées
JP2023527464A (ja) ＳＡＲＭ１の両対立ｋ遺伝子ノックアウト
Li et al. CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Wang et al. CRISPR-Cas9 HDR system enhances AQP1 gene expression
CN113994009B (zh) 用于修饰scn9a或scn10a基因的基因编辑系统及其使用方法
WO2023187639A1 (fr) Molécules d'acide nucléique fonctionnelles pour la régulation épigénétique
AU2022413670A1 (en) Crispr enzymes, methzods, systems and uses thereof
CN114364799B (zh) 编辑造血干/祖细胞中bcl11a基因的方法
Nan et al. Ligase-mediated programmable genomic integration (L-PGI): an efficient site-specific gene editing system that overcomes the limitations of reverse transcriptase-based editing systems
EP4274902A1 (fr) Conceptions d'arn guide et complexes pour systèmes de type v de type sans tracr
US20240309347A1 (en) Fusion Proteins for CRISPR-based Transcriptional Repression
JP2024529400A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ノックアウト
US20250257340A1 (en) Guide nucleic acid identification and methods of use
Yoon et al. CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson’s disease
JP2024542882A (ja) 細胞治療において使用するｓａｒｍ１の発現の減少
WO2024263707A1 (fr) Compositions pour le traitement de la sclérose latérale amyotrophique
WO2025024285A1 (fr) Compositions pour la modification du gène c9orf72 humain
US20220064635A1 (en) Crispr compositions and methods for promoting gene editing of adenosine deaminase 2 (ada2)
TW202523841A (zh) Ⅱ型Ｃａｓ蛋白、ＣＲＩＳＰＲ－Ｃａｓ系統及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23717258

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023717258

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023717258

Country of ref document: EP

Effective date: 20241030